Hookipa Pharma Inc. (HOOK) — SEC Filings
Hookipa Pharma Inc. (HOOK) — 34 SEC filings. Latest: 8-K (Jul 29, 2025). Includes 18 8-K, 4 10-Q, 4 SC 13G/A.
View Hookipa Pharma Inc. on SEC EDGAR
Overview
Hookipa Pharma Inc. (HOOK) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Jul 29, 2025: HOOKIPA Pharma Inc. filed an 8-K on July 29, 2025, to report on the submission of matters to a vote of security holders. The filing does not contain specific details about the matters to be voted on or any associated financial implications.
Sentiment Summary
Across 34 filings, the sentiment breakdown is: 3 bullish, 3 bearish, 28 neutral. The dominant filing sentiment for Hookipa Pharma Inc. is neutral.
Filing Type Overview
Hookipa Pharma Inc. (HOOK) has filed 18 8-K, 1 DEFA14A, 4 10-Q, 1 10-K/A, 2 10-K, 4 SC 13G/A, 2 SC 13G, 1 SC 13D, 1 DEF 14A with the SEC between Jan 2024 to Jul 2025.
Filings by Year
Recent SEC Filings (34)
Risk Profile
Risk Assessment: Of HOOK's 26 recent filings, 1 were flagged as high-risk, 14 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Key Executives
- Dr. Jonathan Lim
- Dr. David Sidransky
- Dr. Jonathan R. Hepple
- Dr. Michael J. Yost
- Dr. Wolfgang Renner
- Felix J. Baker
- Julian C. Baker
Industry Context
HOOKIPA Pharma Inc. operates in the pharmaceutical preparations industry, focusing on developing novel immunotherapies.
Top Tags
biotech (5) · 10-Q (4) · pharmaceuticals (3) · sec-filing (3) · acquisition (3) · merger (3) · filing (3) · corporate-governance (2) · regulatory-filing (2) · annual-report (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Reporting Period End Date | 20250331 | Indicates the end of the fiscal quarter for which financial information is reported. |
| Filing Date | 20250515 | The date the 10-Q report was officially submitted to the SEC. |
| SIC Code | 2834 | Standard Industrial Classification for Pharmaceutical Preparations |
| SEC File Number | 001-38869 | Company's SEC file number |
| Acquisition Price | $300M | Cash amount Roche will pay for HOOKIPA Pharma |
| Cash and Cash Equivalents | $18.55M | As of September 30, 2024, indicating liquidity. |
| Total Assets | $38.78M | As of September 30, 2024, representing the company's total resources. |
| Operating Expenses (YTD) | $24.67M | For the nine months ended September 30, 2024, showing cost of operations. |
| Net Loss (YTD) | $23.99M | For the nine months ended September 30, 2024, highlighting profitability challenges. |
| Total Liabilities | 13.1 | Shows the company's total obligations. |
| Common Stock Issued | 9655022 | Number of common shares outstanding. |
| Series A Convertible Preferred Stock Issued | 96550590 | Number of Series A convertible preferred shares outstanding. |
| Shares Owned | 10,820,641 | Baker Bros. Advisors LP's beneficial ownership in HOOKIPA Pharma Inc. |
| Ownership Stake | 14.9% | Percentage of HOOKIPA Pharma Inc. outstanding shares held by Baker Bros. Advisors LP and its affiliates. |
| Acquisition Value | $1.7B | Total equity value of the deal between HOOKIPA Pharma and Roche. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Hookipa Pharma Inc. (HOOK)?
Hookipa Pharma Inc. has 34 recent SEC filings from Jan 2024 to Jul 2025, including 18 8-K, 4 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of HOOK filings?
Across 34 filings, the sentiment breakdown is: 3 bullish, 3 bearish, 28 neutral. The dominant sentiment is neutral.
Where can I find Hookipa Pharma Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Hookipa Pharma Inc. (HOOK) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Hookipa Pharma Inc.?
Key financial highlights from Hookipa Pharma Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for HOOK?
The investment thesis for HOOK includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Hookipa Pharma Inc.?
Key executives identified across Hookipa Pharma Inc.'s filings include Dr. Jonathan Lim, Dr. David Sidransky, Dr. Jonathan R. Hepple, Dr. Michael J. Yost, Dr. Wolfgang Renner and 2 others.
What are the main risk factors for Hookipa Pharma Inc. stock?
Of HOOK's 26 assessed filings, 1 were flagged high-risk, 14 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Hookipa Pharma Inc.?
Forward guidance and predictions for Hookipa Pharma Inc. are extracted from SEC filings as they are enriched.